Abstract
Onset of tumors in breast cancer is a multi-factorial event at different ages and ethnic populations. The conventional treatment strategy suggests use of anti-estrogen drugs and selective estrogen receptor modulators (SERMs). Although, this strategy has achieved significant success to prevent tumor growth and metastasis and is still developing under an active field of research, the emergence of immunotherapy is a potential modern approach for breast cancer. In addition to SERMs, the screening of selective agonists for toll-like receptor (TLR) signals confers a new area of breast cancer therapy. Recent investigations also indicate significance of TLR signals in the regulation of tumor suppressor p53 gene expression. The TLR agonists have an ability to facilitate activation of natural killer cells, CD8 T cells, B cells, and alpha and beta interferons and induce cellular cytotoxicity. The ongoing developments in cancer research also suggested an approach for intra-tumoral generation of cellular cytotoxicity to induce apoptosis. Both of these events promote destruction of tumor cells in a localized manner and thus, having impact on immunotherapy. Keeping a cautious eye on the context, we propose the prospect of TLR signals in the development of therapy for breast cancer.
Keywords: Breast cancer, immunosuppression, immunotherapy, inflammation, TLR, tumor.
Anti-Cancer Agents in Medicinal Chemistry
Title:Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer
Volume: 15 Issue: 9
Author(s): Christine Zhang, Atheena Ben, Jade Reville, Victoria Calabrese, Nina Nicole Villa, Mausumi Bandyopadhyay and Subhajit Dasgupta
Affiliation:
Keywords: Breast cancer, immunosuppression, immunotherapy, inflammation, TLR, tumor.
Abstract: Onset of tumors in breast cancer is a multi-factorial event at different ages and ethnic populations. The conventional treatment strategy suggests use of anti-estrogen drugs and selective estrogen receptor modulators (SERMs). Although, this strategy has achieved significant success to prevent tumor growth and metastasis and is still developing under an active field of research, the emergence of immunotherapy is a potential modern approach for breast cancer. In addition to SERMs, the screening of selective agonists for toll-like receptor (TLR) signals confers a new area of breast cancer therapy. Recent investigations also indicate significance of TLR signals in the regulation of tumor suppressor p53 gene expression. The TLR agonists have an ability to facilitate activation of natural killer cells, CD8 T cells, B cells, and alpha and beta interferons and induce cellular cytotoxicity. The ongoing developments in cancer research also suggested an approach for intra-tumoral generation of cellular cytotoxicity to induce apoptosis. Both of these events promote destruction of tumor cells in a localized manner and thus, having impact on immunotherapy. Keeping a cautious eye on the context, we propose the prospect of TLR signals in the development of therapy for breast cancer.
Export Options
About this article
Cite this article as:
Zhang Christine, Ben Atheena, Reville Jade, Calabrese Victoria, Villa Nicole Nina, Bandyopadhyay Mausumi and Dasgupta Subhajit, Immunotherapeutic Impact of Toll-like Receptor Agonists in Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (9) . https://dx.doi.org/10.2174/1871520615666150518092547
DOI https://dx.doi.org/10.2174/1871520615666150518092547 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Trizbenzim, Cu-Trizbenzim and Zn-Trizbenzim as G-Quadruplex Inducing and Stabilizing Compounds on Human Telomeric Sequence and their Anticancer Properties
Anti-Cancer Agents in Medicinal Chemistry HDACs and HDAC Inhibitors in Urothelial Carcinoma – Perspectives for an Antineoplastic Treatment
Current Medicinal Chemistry Accessing the Blood-Brain Barrier to Treat Brain Disorders
Current Nanomedicine Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer
Current Topics in Medicinal Chemistry Carotenoids and Cardiovascular Risk
Current Pharmaceutical Design Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design Quantitative Structure Activity Relationship (QSAR) Analysis of Substituted 4-Oxothiazolidines and 5-Arylidines as Lipoxygenase Inhibitors
Mini-Reviews in Medicinal Chemistry Embryonic Morphogenetic Field Induces Phenotypic Reversion in Cancer Cells. Review Article
Current Pharmaceutical Biotechnology The use of Azoles Containing Natural Products in Cancer Prevention and Treatment: An Overview
Anti-Cancer Agents in Medicinal Chemistry Cell Cycle Checkpoint Genes and Aneuploidy: A Short Review
Current Genomics Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology Recent Advances in Selective Estrogen Receptor Modulators for Breast Cancer
Mini-Reviews in Medicinal Chemistry Tissue Elasticity Bridges Cancer Stem Cells to the Tumor Microenvironment Through microRNAs: Implications for a “Watch-and-Wait” Approach to Cancer
Current Stem Cell Research & Therapy The Effect of Claudin-5 Overexpression on the Interactions of Claudin-1 and -2 and Barrier Function in Retinal Cells
Current Molecular Medicine Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Evaluation of Anticancer, Antibacterial and Antioxidant Properties of a Medicinally Treasured Fern Tectaria coadunata with its Phytoconstituents Analysis by HR-LCMS
Anti-Cancer Agents in Medicinal Chemistry Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued)